Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Dova Pharmaceuticals Inc (DOVA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 597,276
  • Shares Outstanding, K 28,200
  • Annual Sales, $ 0 K
  • Annual Income, $ -29,960 K
  • 36-Month Beta 0.30
  • Price/Sales 128.13
  • Price/Cash Flow N/A
  • Price/Book 4.99

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate -0.82
  • Number of Estimates 4
  • High Estimate -0.79
  • Low Estimate -0.88
  • Prior Year -0.38
  • Growth Rate Est. (year over year) -115.79%

Price Performance

See More
Period Period Low Period High Performance
1-Month
19.25 +8.10%
on 10/15/18
25.09 -17.06%
on 09/19/18
-3.67 (-14.99%)
since 09/17/18
3-Month
19.25 +8.10%
on 10/15/18
26.49 -21.44%
on 08/30/18
-3.05 (-12.78%)
since 07/17/18
52-Week
19.25 +8.10%
on 10/15/18
37.00 -43.76%
on 02/20/18
-7.00 (-25.17%)
since 10/17/17

Most Recent Stories

More News
Analysis: Positioning to Benefit within Kopin, MDC Partners, Dova Pharmaceuticals, Revlon, Imprimis Pharmaceuticals, and Minerva Neurosciences -- Research Highlights Growth, Revenue, and Consolidated Results

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Kopin Corporation (NASDAQ:KOPN),...

KOPN : 2.21 (+1.38%)
MDCA : 2.98 (-0.33%)
REV : 26.50 (+1.61%)
IMMY : 3.35 (-3.74%)
DOVA : 20.81 (-1.75%)
NERV : 10.86 (+1.69%)
CORRECTING and REPLACING - Dova Pharmaceuticals and Salix Enter Into Exclusive Co-Promotion Agreement For DOPTELET(R) (Avatrombopag)

In a release issued under the same headline earlier today by Dova Pharmaceuticals, Inc. ("Dova") (NASDAQ: DOVA), please note that the quote by Mark McKenna in the fifth paragraph has been updated.

DOVA : 20.81 (-1.75%)
Dova Pharmaceuticals and Salix Enter Into Exclusive Co-Promotion Agreement For DOPTELET(R) (Avatrombopag)

Dova Pharmaceuticals, Inc. ("Dova") (NASDAQ: DOVA), a specialty pharmaceutical company focused on acquiring, developing, and commercializing drug candidates for diseases where there is a high unmet need,...

DOVA : 20.81 (-1.75%)
Dova Pharmaceuticals to Present at Upcoming Investor Conferences

Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) today announced that Alex Sapir, President and Chief Executive Officer, will present a company overview at two upcoming investor conferences in New York:

DOVA : 20.81 (-1.75%)
Dova Pharmaceuticals to Host Investor & Analyst Day on September 20, 2018

Dova Pharmaceuticals, Inc. (NASDAQ: DOVA), a specialty pharmaceutical company focused on acquiring, developing, and commercializing drug candidates for diseases where there is a high unmet need, today...

DOVA : 20.81 (-1.75%)
Dova Pharmaceuticals Submits Supplemental New Drug Application for DOPTELET(R) (avatrombopag) for the Treatment of Chronic ITP

Dova Pharmaceuticals, Inc. (NASDAQ: DOVA), a specialty pharmaceutical company focused on acquiring, developing, and commercializing drug candidates for diseases where there is a high unmet need, today...

DOVA : 20.81 (-1.75%)
Dova Pharmaceuticals: 2Q Earnings Snapshot

DURHAM, N.C. (AP) _ Dova Pharmaceuticals Inc. (DOVA) on Thursday reported a loss of $19.7 million in its second quarter.

DOVA : 20.81 (-1.75%)
Dova Pharmaceuticals Reports Second Quarter 2018 Operating and Financial Results

DOPTELET approved by FDA on May 21, 2018

DOVA : 20.81 (-1.75%)
Dova Pharmaceuticals to Announce Second Quarter 2018 Financial Results on August 9, 2018

Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) will host a conference call on Thursday, August 9, 2018 at 4:30 p.m. ET to discuss second quarter 2018 financial results and recent operational highlights. A question-and-answer...

DOVA : 20.81 (-1.75%)
Dova Pharmaceuticals: 1Q Earnings Snapshot

DURHAM, N.C. (AP) _ Dova Pharmaceuticals Inc. (DOVA) on Wednesday reported a loss of $13.8 million in its first quarter.

DOVA : 20.81 (-1.75%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade DOVA with:

Business Summary

Dova Pharmaceuticals, Inc. is a pharmaceutical company. It focuses on acquiring, developing and commercializing drug candidates for thrombocytopenia diseases. The company's drug candidate includes avatrombopag, an orally administered thrombopoietin receptor agonist which are in clinical stage. Dova Pharmaceuticals,...

See More

Key Turning Points

2nd Resistance Point 21.83
1st Resistance Point 21.32
Last Price 20.81
1st Support Level 20.22
2nd Support Level 19.63

See More

52-Week High 37.00
Fibonacci 61.8% 30.22
Fibonacci 50% 28.13
Fibonacci 38.2% 26.03
Last Price 20.81
52-Week Low 19.25

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar